Athira Pharma Securities Settlement ($10 million)

If you purchased or otherwise acquired Athira Pharma, Inc. publicly traded common stock from September 17, 2020, through June 17, 2021, inclusive, you may be eligible to claim an award from a class action settlement.

Athira Pharma, Inc. has agreed to pay $10,000,000 to settle a class action lawsuit for alleged false and misleading statements related to altered images in certain research papers co-authored by Dr. Kawas.

Who can submit a claim?

To be eligible to submit a claim, you must be a member of the Class. This includes all persons and entities who purchased or otherwise acquired Athira Pharma, Inc. publicly traded common stock during the period from September 17, 2020, through June 17, 2021, inclusive, and were damaged thereby.

There are two subclasses within the Class:

• Securities Act Subclass: All persons and entities who purchased or otherwise acquired Athira Pharma, Inc. publicly traded common stock during the period from September 17, 2020, through March 16, 2021, inclusive, and were damaged thereby.
• Exchange Act Subclass: All persons and entities who purchased or otherwise acquired Athira Pharma, Inc. publicly traded common stock during the period from March 17, 2021, through June 17, 2021, inclusive, and were damaged thereby.

How much can class members get?

The amount that class members can receive from the settlement depends on several factors, including the number of shares they purchased, when they purchased them, and whether they sold them. The Net Settlement Fund will be distributed to Class Members who submit valid Claim Forms, in accordance with the proposed Plan of Allocation.

The proposed Plan of Allocation provides formulas for calculating Claims and states that up to 8.5% of the Net Settlement Fund will be allocated to Authorized Claimants’ Exchange Act Claims and no less than 91.5% of the Net Settlement Fund will be allocated to Authorized Claimants’ Securities Act Claims.

• Securities Act Claims: Claims relating to Athira’s publicly traded common stock acquired in connection with its IPO and SPO during the period from September 17, 2020, through March 16, 2021.
• Exchange Act Claims: Claims relating to Athira’s publicly traded common stock acquired from March 17, 2021, through June 17, 2021.

For example, a Class Member with a Securities Act Claim who purchased 1,000 eligible shares might receive a payment of $470.00, and a Class Member with an Exchange Act Claim who purchased 1,000 eligible shares may receive a payment of $60.00.

Is proof required to submit a claim?

Yes, claimants need to provide proof to claim an award. Claimants must submit copies of broker confirmations or other documentation of their transactions in Athira common stock.

• Proof of purchase or acquisition of Athira common stock during the Class Period.
• Proof of sale of Athira common stock, if applicable.
• Proof of holding Athira common stock at the close of trading on June 25, 2021, and September 15, 2021.

How to claim an award

To claim an award, you can submit your claim online or by mail. To file a claim online, visit the online claim form. For mailed submissions, send your completed and signed Claim Form, along with the required documentation, to:

Athira Pharma Securities Litigation

c/o Strategic Claims Services

P.O. Box 230

600 N. Jackson Street, Suite 205

Media, PA 19063

Ensure that your claim is postmarked or submitted online no later than September 6, 2024.

Payments to class members

Payments will be made to Authorized Claimants who submit valid Claim Forms. The Settlement Administrator will distribute the Net Settlement Fund to Authorized Claimants on a pro rata basis based on the relative size of their Securities Act Claims and Exchange Act Claims.

$10,000,000 Settlement Fund

The settlement fund of $10,000,000 will cover various costs and payments:

• Taxes: Estimated at approximately $200,000.
• Notice and Administration Costs: Estimated at approximately $200,000.
• Escrow fees: Approximately $5,200 per year.
• Litigation Expenses: Estimated at no more than $235,000.
• Attorneys’ fees: Estimated at no more than 33⅓% of the Settlement Fund.

The remaining amount, referred to as the Net Settlement Fund, will be distributed to Class Members who submit valid Claim Forms.

Important dates

• Deadline to File a Claim: September 6, 2024
• Final Approval Hearing: October 25, 2024

When is the Athira Pharma payout date?

The awards will be paid after the Court approves the Settlement and any appeals are resolved.

What happens next?

1. Class Members submit their Claim Forms by the deadline to be eligible for a payment.
2. The Court will hold a Final Approval Hearing on October 25, 2024, to decide whether to approve the Settlement, the Plan of Allocation, and the motion for attorneys’ fees and Litigation Expenses.